MURA beat EPS expectations by 7.55%
May 22, 2025, 10:33 PM
0.00%
What does MURA do
Mural Oncology Plc is a clinical-stage company developing cytokine-based immunotherapies for cancer using its protein engineering platform. Its portfolio includes Nemvaleukin alfa and a tumor-targeted split IL-12 program.
Mural Oncology plc (MURA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Mural Oncology plc's actual EPS was -$1.93, beating the estimate of -$2.09 per share, resulting in a 7.55% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.